Acadia Pharmaceuticals | ACAD - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
ALKERMES USD 351.55M 37.02M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Cara Therapeutics USD 20.73M 684K 2025-12
Corcept Therapeutics USD 108.74M 11.76M 2026-03
Cytokinetics USD 129.84M 7.32M 2026-03
Eisai JPY 301.65B 16.27B 2025-09
Eli Lilly USD 5.28B 1.99B 2026-03
Incyte USD 4.02B 435.22M 2026-03
J&J USD 21.69B 1.98B 2026-03
Moderna USD 1.91B 687M 2026-03
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Pfizer USD 1.7B 561M 2026-03
Prothena USD 329.46M 21.93M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03